title: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
abstract: The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved. We conducted a prospective, multicentered, phase II trial. A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors. The primary study end point was non-relapse mortality (NRM). Histologies were non-Hodgkin's lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL), n=14) and Hodgkin's disease (HD, n=32). Median follow-up was 33 months (range, 12-82). The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001). Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04). Molecular remission occurred in 94 and 40% (P=0.002) of patients with FL and CLL, respectively. On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of HD (HR=3.5), and acute GVHD (HR=5.9). RIC allogeneic SCT is a feasible and effective salvage strategy in both indolent and aggressive NHL.
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Department of Hematology, Istituto Nazionale per lo Studio e la Cura dei Tumori, University of Milano, Milan, Italy. paolo.corradini@istitutotumori.mi.it
authors.forename: P
authors.initials: P
authors.lastname: Corradini
authors.forename: A
authors.initials: A
authors.lastname: Dodero
authors.forename: L
authors.initials: L
authors.lastname: Farina
authors.forename: R
authors.initials: R
authors.lastname: Fanin
authors.forename: F
authors.initials: F
authors.lastname: Patriarca
authors.forename: R
authors.initials: R
authors.lastname: Miceli
authors.forename: P
authors.initials: P
authors.lastname: Matteucci
authors.forename: M
authors.initials: M
authors.lastname: Bregni
authors.forename: R
authors.initials: R
authors.lastname: Scimè
authors.forename: F
authors.initials: F
authors.lastname: Narni
authors.forename: E
authors.initials: E
authors.lastname: Pogliani
authors.forename: A
authors.initials: A
authors.lastname: Locasciulli
authors.forename: R
authors.initials: R
authors.lastname: Milani
authors.forename: C
authors.initials: C
authors.lastname: Carniti
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: A
authors.initials: A
authors.lastname: Rambaldi
authors.forename: F
authors.initials: F
authors.lastname: Bonifazi
authors.forename: A
authors.initials: A
authors.lastname: Olivieri
authors.forename: A M
authors.initials: AM
authors.lastname: Gianni
authors.forename: C
authors.initials: C
authors.lastname: Tarella
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods; D016896:Treatment Outcome